Viridian Therapeutics, Inc. (VRDN) is a publicly traded company in the Healthcare — Biotechnology industry listed on NASDAQ. This overview shows the latest price, key valuation ratios, profitability metrics and financial-health indicators used by fundamental investors.
Viridian Therapeutics, Inc. is a biotechnology firm committed to creating therapies for patients afflicted by serious illnesses. Its primary development efforts include VRDN-001, a humanized monoclonal anti-IGF-1R antibody currently advancing through Phase 1/2 clinical trials for thyroid eye disease (TED).
Is Viridian Therapeutics, Inc. stock overvalued or undervalued in 2026?
As of October 30, 2026, Viridian Therapeutics, Inc. (VRDN) trades at $24.67 with no positive earnings over the last twelve months, according to Kaplio. No valuation verdict: it has no earnings to calculate a P/E from.
Kaplio overview: Viridian Therapeutics, Inc.
Market cap $3B · 52 weeks $13 – $34 (27 % below the high) · P/E no earnings · Dividend none · Next earnings November 4, 2026 · expected EPS $-1.02 · Closing price, Oct 30 · accounts published Aug 6.
- Valuation: P/Sales 16.1× (no earnings).
- Balance sheet: Safe zone (solid).
- Earnings: 4 of 8 (uneven).
What would it be worth at its usual multiples?
No valuation verdict: it has no earnings to calculate a P/E from.
What matters in biotech: 4 of 4 pass
- Cash Runway 38 meses, passes.
- Total Debt 0.1×, passes.
- R&D / Market cap 16.2 %, passes.
- Market cap / Cash 2.4×, passes.
- Annual cash burn $3.26, info.
Against its peers (reference peers) — Viridian Therapeutics, Inc.: P/E —; EV/EBITDA —; ROIC -39.2 %; $2.8B. Nurix Therapeutics, Inc. (P/E 11.6×; EV/EBITDA 7.0×; ROIC 25.9 %; $2.9B), ADMA Biologics, Inc. (P/E 16.3×; EV/EBITDA 11.6×; ROIC 27.6 %; $2.6B), Telix Pharmaceuticals Limited (P/E 94.9×; EV/EBITDA 114×; ROIC -0.6 %; $3.1B).
Profitability
| Return on Equity | -61.35% |
| Return on Invested Capital | -39.18% |
| Return on Assets | -35.27% |
| Gross Margin | 99.55% |
| Operating Margin | -569.68% |
| Net Margin | -544.06% |
Financial Health
| Debt / Equity | 0.37 |
| Current Ratio | 16.95 |
| Piotroski F-Score | 2 |
| Altman Z-Score | 6.69 |
Price Performance
| 1 month | +29.91% |
| 3 months | +30.39% |
| Year-to-date | -20.73% |
| 1 year | +4.40% |
| 3 years | +95.79% |
| 5 years | +36.07% |
| 10 years | -69.54% |
Related companies: VRTX · 0QZU.L · REGN · MRNA · 0R2M.L · ARGX · 0QNO.L · RVMD
Explore sector: Healthcare · Biotechnology
More sections of VRDN: Financials · Valuation · Statistics · Estimates · Technical · Ownership · News · Events
Discover more: Weekly Radar: the S&P 500 through the Buffett and Lynch methods · Companies that pass the Buffett method today · Companies that pass the Lynch method today · Stocks that pass Graham's defensive investor test today · Investment Academy — learn to analyze stocks